Tyk2 Targeting in Immune-Mediated Inflammatory Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Feb 25

PMID 36834806

Authors

Lluis Rusinol

Luis Puig

Affiliations

Soon will be listed here.

Abstract

The Janus kinase (Jak)/signal transducer and activating protein (STAT) pathways mediate the intracellular signaling of cytokines in a wide spectrum of cellular processes. They participate in physiologic and inflammatory cascades and have become a major focus of research, yielding novel therapies for immune-mediated inflammatory diseases (IMID). Genetic linkage has related dysfunction of Tyrosine kinase 2 (Tyk2)-the first member of the Jak family that was described-to protection from psoriasis. Furthermore, Tyk2 dysfunction has been related to IMID prevention, without increasing the risk of serious infections; thus, Tyk2 inhibition has been established as a promising therapeutic target, with multiple Tyk2 inhibitors under development. Most of them are orthosteric inhibitors, impeding adenosine triphosphate (ATP) binding to the JH1 catalytic domain-which is highly conserved across tyrosine kinases-and are not completely selective. Deucravacitinib is an allosteric inhibitor that binds to the pseudokinase JH2 (regulatory) domain of Tyk2; this unique mechanism determines greater selectivity and a reduced risk of adverse events. In September 2022, deucravacitinib became the first Tyk2 inhibitor approved for the treatment of moderate-to-severe psoriasis. A bright future can be expected for Tyk2 inhibitors, with newer drugs and more indications to come.

Citing Articles

Hyper IgE Syndrome: Bridging the Gap Between Immunodeficiency, Atopy, and Allergic Diseases.

Sutanto H, Adytia G, Fetarayani D Curr Allergy Asthma Rep. 2025; 25(1):17.

PMID: 40082265 DOI: 10.1007/s11882-025-01196-8.

JAK inhibitors: a new choice for diabetes mellitus?.

Zhou M, Shen Q, Li B Diabetol Metab Syndr. 2025; 17(1):33.

PMID: 39849637 PMC: 11755809. DOI: 10.1186/s13098-025-01582-2.

Association of tyrosine kinase 2 polymorphisms with susceptibility to microscopic polyangiitis in a Guangxi population.

Yang B, Chu L, Feng F, Lu S, Xue C PeerJ. 2024; 12:e18735.

PMID: 39726748 PMC: 11670758. DOI: 10.7717/peerj.18735.

JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician.

Beard A, Trotter S J Family Med Prim Care. 2024; 13(10):4128-4134.

PMID: 39629448 PMC: 11610805. DOI: 10.4103/jfmpc.jfmpc_112_24.

Lack of TYK2 signaling enhances host resistance to Candida albicans skin infection.

Miranda S, Lassnig C, Schmidhofer K, Kjartansdottir H, Vogl C, Tangermann S Nat Commun. 2024; 15(1):10493.

PMID: 39622833 PMC: 11612186. DOI: 10.1038/s41467-024-54888-6.

References

Markota cagalj A, Marinovic B, Bukvic Mokos Z . New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int J Mol Sci. 2022; 23(7). PMC: 8998913. DOI: 10.3390/ijms23073753. View

. Efficacy and Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Moderately to Severely Active Ulcerative Colitis: 12-Week Results From the Phase 2 LATTICE-UC Study. Gastroenterol Hepatol (N Y). 2023; 18(7 Suppl 2):6. PMC: 9671062. View

Nogueira M, Torres T . Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib. Dermatol Pract Concept. 2022; 11(4):e2021145. PMC: 8648435. DOI: 10.5826/dpc.1104a145. View

Baker K, Isaacs J . Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?. Ann Rheum Dis. 2017; 77(2):175-187. DOI: 10.1136/annrheumdis-2017-211555. View

Tokarski J, Zupa-Fernandez A, Tredup J, Pike K, Chang C, Xie D . Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. J Biol Chem. 2015; 290(17):11061-74. PMC: 4409266. DOI: 10.1074/jbc.M114.619502. View

Liu C, Lin J, Langevine C, Smith D, Li J, Tokarski J . Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. J Med Chem. 2020; 64(1):677-694. DOI: 10.1021/acs.jmedchem.0c01698. View

Works M, Yin F, Yin C, Yiu Y, Shew K, Tran T . Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. J Immunol. 2014; 193(7):3278-87. PMC: 4170002. DOI: 10.4049/jimmunol.1400205. View

Ma H, Liang S, Li J, Napierata L, Brown T, Benoit S . IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008; 118(2):597-607. PMC: 2200300. DOI: 10.1172/JCI33263. View

Garcia-Melendo C, Cubiro X, Puig L . Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses. Actas Dermosifiliogr (Engl Ed). 2021; 112(7):586-600. DOI: 10.1016/j.adengl.2021.05.008. View

10.

Furie R, Khamashta M, Merrill J, Werth V, Kalunian K, Brohawn P . Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017; 69(2):376-386. PMC: 5299497. DOI: 10.1002/art.39962. View

11.

Ghoreschi K, Laurence A, OShea J . Janus kinases in immune cell signaling. Immunol Rev. 2009; 228(1):273-87. PMC: 2782696. DOI: 10.1111/j.1600-065X.2008.00754.x. View

12.

Sohn S, Barrett K, Van Abbema A, Chang C, Kohli P, Kanda H . A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol. 2013; 191(5):2205-16. PMC: 3748334. DOI: 10.4049/jimmunol.1202859. View

13.

Banfield C, Scaramozza M, Zhang W, Kieras E, Page K, Fensome A . The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. J Clin Pharmacol. 2017; 58(4):434-447. DOI: 10.1002/jcph.1046. View

14.

Ishizaki M, Muromoto R, Akimoto T, Sekine Y, Kon S, Diwan M . Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol. 2013; 26(5):257-67. DOI: 10.1093/intimm/dxt062. View

15.

Catlett I, Hu Y, Gao L, Banerjee S, Gordon K, Krueger J . Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2021; 149(6):2010-2020.e8. DOI: 10.1016/j.jaci.2021.11.001. View

16.

Moslin R, Zhang Y, Wrobleski S, Lin S, Mertzman M, Spergel S . Identification of -Methyl Nicotinamide and -Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2). J Med Chem. 2019; 62(20):8953-8972. DOI: 10.1021/acs.jmedchem.9b00443. View

17.

McInnes I, Kato K, Magrey M, Merola J, Kishimoto M, Haaland D . Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study. Rheumatol Ther. 2022; 10(1):275-292. PMC: 9569172. DOI: 10.1007/s40744-022-00499-w. View

18.

Guttman-Yassky E, Pavel A, Diaz A, Zhang N, Del Duca E, Estrada Y . Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2021; 149(4):1318-1328. DOI: 10.1016/j.jaci.2021.10.036. View

19.

Wrobleski S, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J . Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019; 62(20):8973-8995. DOI: 10.1021/acs.jmedchem.9b00444. View

20.

Kreins A, Ciancanelli M, Okada S, Kong X, Ramirez-Alejo N, Kilic S . Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med. 2015; 212(10):1641-62. PMC: 4577846. DOI: 10.1084/jem.20140280. View